JoVE Logo

로그인

ConceptExperiment

JoVE 비디오를 활용하시려면 도서관을 통한 기관 구독이 필요합니다.

Sulforhodamine B Assay: A Sensitive Assay to Measure Drug Resistance Via Determination of Cellular Protein Content in Cancer Cells

-- views • 2:01 min

내레이션 대본

Sulforhodamine B or SRB assay allows cell density determination based on the measurement of cellular protein content. To begin the assay, pipette a suspension of desired drug-sensitive parental cancer cells and their drug-resistant variant into wells of a multi-well plate.

Incubate to allow the cells to adhere to the plate. Treat both the cell types with a range of increasing concentrations of the specific drug and incubate. 

In culture, the drug-sensitive cancer cells are susceptible to the drug molecules and undergo cell death even at low concentrations. In contrast, the drug-resistant cancer cells withstand the effect of drug molecules and survive and proliferate even at higher drug concentrations.

Next, add an appropriate concentration of trichloroacetic acid or TCA to the culture. TCA - a mild acid - permeabilizes the cells and disrupts the electrostatic interactions and native protein conformations, leading to protein denaturation.

Incubate with Sulforhodamine B solution. Under mild acidic conditions, sulforhodamine B - a protein-binding dye - binds stoichiometrically to basic amino acid residues of proteins.

Rinse with acetic acid to remove any unbound dye. Now, treat the sample with a Tris base solution. The basic environment dissociates the dye molecules from the amino acid residues, releasing them into solution. 

Finally, use a microplate reader to measure the released dye molecules. The wells containing drug-resistant cancer cells show higher color intensity, indicating increased cell density compared to the drug-sensitive variant cells.

article

01:56

Sulforhodamine B Assay: A Sensitive Assay to Measure Drug Resistance Via Determination of Cellular Protein Content in Cancer Cells

관련 동영상

1.1K Views

JoVE Logo

개인 정보 보호

이용 약관

정책

연구

교육

JoVE 소개

Copyright © 2025 MyJoVE Corporation. 판권 소유